A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators

Dissociation of the transactivating and transreppressive activities

Nicolas C. Nicolaides, Michael L. Roberts, Tomoshige Kino, Geoffrey Braatvedt, Darrell E. Hurt, Eleni Katsantoni, Amalia Sertedaki, George P. Chrousos, Evangelia Charmandari

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Context: Primary generalized glucocorticoid resistance is a rare genetic disorder characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. The molecular basis of the condition has been ascribed to inactivating mutations in the human glucocorticoid receptor (hGR) gene. Objective: The objective of the study was to present three new cases caused by a novel mutation in the hGR gene and to delineate the molecular mechanisms through which the mutant receptor impairs glucocorticoid signal transduction. Design and Results: The index case (father) and his two daughters presented with increased urinary free cortisol excretion and resistance of the hypothalamic-pituitary-adrenal axis to dexamethasone suppression in the absence of clinical manifestations suggestive of Cushing syndrome. All subjects harbored a novel, heterozygous, point mutation (T3G) at nucleotide position 1724 of the hGR gene, which resulted in substitution of valine by glycine at amino acid 575 of the receptor. Compared with the wild-type receptor, the hGRV575G demonstrated a significant (33%) reduction in its ability to transactivate the mouse mammary tumor virus promoter in response to dexamethasone, a 50% decrease in its affinity for the ligand, and a 2.5-fold delay in nuclear translocation. Although it did not exert a dominant negative effect on the wild-type receptor and preserved its ability to bind to DNA, hGRαV575G displayed significantly enhanced (~80%) ability to transrepress the nuclear factor-κ signaling pathway. Finally, the mutant receptor hGRαV575G demonstrated impaired interaction with the LXXLL motif of the glucocorticoid receptor-interacting protein 1 coactivator in vitro and in computer- based structural simulation via its defective activation function-2 (AF-2) domain. Conclusions: The natural mutant receptor hGRαV575G causes primary generalized glucocorticoid resistance by affecting multiple steps in the glucocorticoid signaling cascade, including the affinity for the ligand, the time required for nuclear translocation, and the interaction with the glucocorticoid- interacting protein-1 coactivator.

Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number5
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Glucocorticoid Receptors
Point Mutation
Glucocorticoids
Aptitude
Genes
Dexamethasone
Nuclear Receptor Coactivator 2
Amino Acid Receptors
Ligands
Mouse mammary tumor virus
Mutation
Inborn Genetic Diseases
Cushing Syndrome
Valine
Nuclear Family
Signal transduction
Fathers
Carcinogens
Glycine
Hydrocortisone

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators : Dissociation of the transactivating and transreppressive activities. / Nicolaides, Nicolas C.; Roberts, Michael L.; Kino, Tomoshige; Braatvedt, Geoffrey; Hurt, Darrell E.; Katsantoni, Eleni; Sertedaki, Amalia; Chrousos, George P.; Charmandari, Evangelia.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 5, 2014.

Research output: Contribution to journalArticle

@article{b71defaacc214dc89dd8bbfbfcf757ce,
title = "A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: Dissociation of the transactivating and transreppressive activities",
abstract = "Context: Primary generalized glucocorticoid resistance is a rare genetic disorder characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. The molecular basis of the condition has been ascribed to inactivating mutations in the human glucocorticoid receptor (hGR) gene. Objective: The objective of the study was to present three new cases caused by a novel mutation in the hGR gene and to delineate the molecular mechanisms through which the mutant receptor impairs glucocorticoid signal transduction. Design and Results: The index case (father) and his two daughters presented with increased urinary free cortisol excretion and resistance of the hypothalamic-pituitary-adrenal axis to dexamethasone suppression in the absence of clinical manifestations suggestive of Cushing syndrome. All subjects harbored a novel, heterozygous, point mutation (T3G) at nucleotide position 1724 of the hGR gene, which resulted in substitution of valine by glycine at amino acid 575 of the receptor. Compared with the wild-type receptor, the hGRV575G demonstrated a significant (33{\%}) reduction in its ability to transactivate the mouse mammary tumor virus promoter in response to dexamethasone, a 50{\%} decrease in its affinity for the ligand, and a 2.5-fold delay in nuclear translocation. Although it did not exert a dominant negative effect on the wild-type receptor and preserved its ability to bind to DNA, hGRαV575G displayed significantly enhanced (~80{\%}) ability to transrepress the nuclear factor-κ signaling pathway. Finally, the mutant receptor hGRαV575G demonstrated impaired interaction with the LXXLL motif of the glucocorticoid receptor-interacting protein 1 coactivator in vitro and in computer- based structural simulation via its defective activation function-2 (AF-2) domain. Conclusions: The natural mutant receptor hGRαV575G causes primary generalized glucocorticoid resistance by affecting multiple steps in the glucocorticoid signaling cascade, including the affinity for the ligand, the time required for nuclear translocation, and the interaction with the glucocorticoid- interacting protein-1 coactivator.",
author = "Nicolaides, {Nicolas C.} and Roberts, {Michael L.} and Tomoshige Kino and Geoffrey Braatvedt and Hurt, {Darrell E.} and Eleni Katsantoni and Amalia Sertedaki and Chrousos, {George P.} and Evangelia Charmandari",
year = "2014",
doi = "10.1210/jc.2013-3005",
language = "English",
volume = "99",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators

T2 - Dissociation of the transactivating and transreppressive activities

AU - Nicolaides, Nicolas C.

AU - Roberts, Michael L.

AU - Kino, Tomoshige

AU - Braatvedt, Geoffrey

AU - Hurt, Darrell E.

AU - Katsantoni, Eleni

AU - Sertedaki, Amalia

AU - Chrousos, George P.

AU - Charmandari, Evangelia

PY - 2014

Y1 - 2014

N2 - Context: Primary generalized glucocorticoid resistance is a rare genetic disorder characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. The molecular basis of the condition has been ascribed to inactivating mutations in the human glucocorticoid receptor (hGR) gene. Objective: The objective of the study was to present three new cases caused by a novel mutation in the hGR gene and to delineate the molecular mechanisms through which the mutant receptor impairs glucocorticoid signal transduction. Design and Results: The index case (father) and his two daughters presented with increased urinary free cortisol excretion and resistance of the hypothalamic-pituitary-adrenal axis to dexamethasone suppression in the absence of clinical manifestations suggestive of Cushing syndrome. All subjects harbored a novel, heterozygous, point mutation (T3G) at nucleotide position 1724 of the hGR gene, which resulted in substitution of valine by glycine at amino acid 575 of the receptor. Compared with the wild-type receptor, the hGRV575G demonstrated a significant (33%) reduction in its ability to transactivate the mouse mammary tumor virus promoter in response to dexamethasone, a 50% decrease in its affinity for the ligand, and a 2.5-fold delay in nuclear translocation. Although it did not exert a dominant negative effect on the wild-type receptor and preserved its ability to bind to DNA, hGRαV575G displayed significantly enhanced (~80%) ability to transrepress the nuclear factor-κ signaling pathway. Finally, the mutant receptor hGRαV575G demonstrated impaired interaction with the LXXLL motif of the glucocorticoid receptor-interacting protein 1 coactivator in vitro and in computer- based structural simulation via its defective activation function-2 (AF-2) domain. Conclusions: The natural mutant receptor hGRαV575G causes primary generalized glucocorticoid resistance by affecting multiple steps in the glucocorticoid signaling cascade, including the affinity for the ligand, the time required for nuclear translocation, and the interaction with the glucocorticoid- interacting protein-1 coactivator.

AB - Context: Primary generalized glucocorticoid resistance is a rare genetic disorder characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. The molecular basis of the condition has been ascribed to inactivating mutations in the human glucocorticoid receptor (hGR) gene. Objective: The objective of the study was to present three new cases caused by a novel mutation in the hGR gene and to delineate the molecular mechanisms through which the mutant receptor impairs glucocorticoid signal transduction. Design and Results: The index case (father) and his two daughters presented with increased urinary free cortisol excretion and resistance of the hypothalamic-pituitary-adrenal axis to dexamethasone suppression in the absence of clinical manifestations suggestive of Cushing syndrome. All subjects harbored a novel, heterozygous, point mutation (T3G) at nucleotide position 1724 of the hGR gene, which resulted in substitution of valine by glycine at amino acid 575 of the receptor. Compared with the wild-type receptor, the hGRV575G demonstrated a significant (33%) reduction in its ability to transactivate the mouse mammary tumor virus promoter in response to dexamethasone, a 50% decrease in its affinity for the ligand, and a 2.5-fold delay in nuclear translocation. Although it did not exert a dominant negative effect on the wild-type receptor and preserved its ability to bind to DNA, hGRαV575G displayed significantly enhanced (~80%) ability to transrepress the nuclear factor-κ signaling pathway. Finally, the mutant receptor hGRαV575G demonstrated impaired interaction with the LXXLL motif of the glucocorticoid receptor-interacting protein 1 coactivator in vitro and in computer- based structural simulation via its defective activation function-2 (AF-2) domain. Conclusions: The natural mutant receptor hGRαV575G causes primary generalized glucocorticoid resistance by affecting multiple steps in the glucocorticoid signaling cascade, including the affinity for the ligand, the time required for nuclear translocation, and the interaction with the glucocorticoid- interacting protein-1 coactivator.

UR - http://www.scopus.com/inward/record.url?scp=84899991790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899991790&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-3005

DO - 10.1210/jc.2013-3005

M3 - Article

VL - 99

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -